ATE169957T1 - Verfahren zur herstellung des inhibitors für die komplexbildung des gewebefaktors - Google Patents

Verfahren zur herstellung des inhibitors für die komplexbildung des gewebefaktors

Info

Publication number
ATE169957T1
ATE169957T1 AT93870037T AT93870037T ATE169957T1 AT E169957 T1 ATE169957 T1 AT E169957T1 AT 93870037 T AT93870037 T AT 93870037T AT 93870037 T AT93870037 T AT 93870037T AT E169957 T1 ATE169957 T1 AT E169957T1
Authority
AT
Austria
Prior art keywords
tfpi
purifying
exchange chromatography
sulfonate
refolding
Prior art date
Application number
AT93870037T
Other languages
German (de)
English (en)
Inventor
Judith Arlene Diaz-Collier
Mark Edward Gustafson
Tze-Chein Wun
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of ATE169957T1 publication Critical patent/ATE169957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93870037T 1992-03-02 1993-03-01 Verfahren zur herstellung des inhibitors für die komplexbildung des gewebefaktors ATE169957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,297 US5212091A (en) 1992-03-02 1992-03-02 Method of producing tissue factor pathway inhibitor

Publications (1)

Publication Number Publication Date
ATE169957T1 true ATE169957T1 (de) 1998-09-15

Family

ID=25292320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93870037T ATE169957T1 (de) 1992-03-02 1993-03-01 Verfahren zur herstellung des inhibitors für die komplexbildung des gewebefaktors

Country Status (7)

Country Link
US (1) US5212091A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0559632B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3333846B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE169957T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2090650C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69320389T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0559632T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
GB9215541D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
WO1996004377A1 (en) * 1994-08-05 1996-02-15 Chiron Corporation Production of tissue factor pathway inhibitor
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
DE69637012T2 (de) * 1995-06-07 2009-01-08 G.D. Searle Llc (N.D.Ges.D. Staates Delaware) Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
AU781717B2 (en) * 1998-04-24 2005-06-09 Csl Behring Gmbh Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US6794159B1 (en) 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
JP2005506345A (ja) * 2001-10-15 2005-03-03 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1941867E (pt) * 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
EP1654283B1 (en) * 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN101262879B (zh) * 2005-06-24 2013-04-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用活化的蛋白c
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
WO2007079096A2 (en) 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
KR101179171B1 (ko) 2008-08-14 2012-09-03 주식회사 운화 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
WO1993025230A1 (en) * 1992-06-11 1993-12-23 G.D. Searle & Co. Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders

Also Published As

Publication number Publication date
EP0559632A2 (en) 1993-09-08
DE69320389T2 (de) 1999-03-11
DK0559632T3 (da) 1998-10-26
EP0559632A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-03-29
EP0559632B1 (en) 1998-08-19
DE69320389D1 (de) 1998-09-24
JPH07274968A (ja) 1995-10-24
CA2090650A1 (en) 1993-09-03
CA2090650C (en) 2008-01-29
JP3333846B2 (ja) 2002-10-15
US5212091A (en) 1993-05-18

Similar Documents

Publication Publication Date Title
ATE169957T1 (de) Verfahren zur herstellung des inhibitors für die komplexbildung des gewebefaktors
DE3783273T2 (de) Methode fuer das zusammensetzen einer kette.
MY103892A (en) Interleukin-2 of high purity production and use
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
HK8694A (en) Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
KR960703433A (ko) 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ATE56729T1 (de) Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung.
DE91543T1 (de) Anti-interferon antikoerper und verfahren zu deren herstellung.
ATE107850T1 (de) In einem dna - gel stabilisierte heilwasserliposomen.
IT1232670B (it) Procedimento per la purificazione delle acque reflue prodotte dagli impianti di produzione dell'urea.
DE3485488D1 (de) Imidazoliumsalze, zwischenprodukte fuer ihre herstellung sowie ihre verwendung.
ATE40681T1 (de) Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten.
FI931332A0 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
ATA278988A (de) Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
DK102892A (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
WO1997023507A3 (en) New form of amphiregulin, methods for producing and using the same and compositions comprising the same
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
ATE113209T1 (de) Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
DE68928634D1 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
DE69021128D1 (de) Interleukin-1-Inhibitor.
DE69031596T2 (de) Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
DE59007103D1 (de) Verfahren zur Herstellung von Di-(p-glycidoxicyclohexyl)-methan.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee